NEW YORK (GenomeWeb News) – Compugen said today that it will receive grants totaling around $500,000 from the Office of the Chief Scientist of Israel to fund the firm's drug and diagnostic product candidate discovery activities.

Tel Aviv, Israel-based Compugen said that it would use the grant money to discover additional drug targets for antibody therapeutics and preclinical nucleic acid biomarkers for drug-induced toxicity. The firm said these activities would be based on "modifying and enhancing" its 10 existing discovery platforms.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

The Jackson Laboratory has filed a complaint accusing Nanjing University of breeding and re-selling its mouse models, the Hartford Courant reports.

Oxford researchers are turning to virtual reality to visualize genes and regulatory elements, Phys.org says.

In Science this week: neutrophils rely on microRNA to protect against lung inflammation, and more.

China is moving forward with plans to sequence a million citizens, the Wall Street Journal reports.